{"id":"W4410811580","doi":"10.1200/jco.2025.43.16_suppl.5057","title":"Substudy F of the Canadian Cancer Trials Group (CCTG) IND.234: PC_BETS (Prostate Cancer Biomarker Enrichment and Treatment Selection)—A biomarker-selected phase II study of durvalumab and tremelilumab (DT) in patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC) resistant to AR pathway inhibitors (ARPI).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; Western University; McGill University; Jewish General Hospital; Ottawa Hospital; BC Cancer Agency; Queen's University; London Health Sciences Centre; McMaster University; Cancer Care Ontario; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Biomarker; Durvalumab; Cancer; Prostate cancer; Oncology; Internal medicine; Urothelial cancer; Prostate; Bladder cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001925256,0.001146738,0.001370119,0.0004398434,0.000691675,0.0006834177,0.0009147187,0.001197926,0.007168586],"category_scores_gemma":[0.001642693,0.0004156188,0.001476917,0.0009371829,0.0004625775,0.0002748331,0.0003329656,0.001276304,0.0008760497],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003394437,"about_ca_system_score_gemma":0.007854822,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.07230932,"about_ca_topic_score_gemma":0.2356109,"domain_scores_codex":[0.9992998,0.0003297413,0.00003531764,0.00007625324,0.0001112384,0.0001477376],"domain_scores_gemma":[0.9991285,0.0001301128,0.0002121599,0.00008465941,0.0001242243,0.0003203152],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8241212,0.00527865,0.01279052,0.002646898,0.003504601,0.0001877367,0.0001933253,0.001901341,0.01273469,0.001084325,0.05854373,0.07701286],"study_design_scores_gemma":[0.793328,0.07202829,0.08487919,0.0003649346,0.002806158,0.0002487468,0.00007439638,0.0009556716,0.002269905,0.0005646981,0.04240895,0.00007106166],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8131799,0.009058682,0.001125226,0.003613036,0.000690268,0.05175807,0.08849657,0.0003115147,0.03176667],"genre_scores_gemma":[0.8566954,0.00638231,0.005444967,0.00562006,0.0006886724,0.04519559,0.06157827,0.0001414751,0.01825335],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07230932,"threshold_uncertainty_score":0.1437768,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1127765532495396,"score_gpt":0.4520381964419235,"score_spread":0.3392616431923839,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}